

BIO5192 hydrate Biochemical | BIO5192 biochemical

BIO5192 hydrate

CATALOG #
AAA227132


PRODUCT SYNONYMS

BIO5192 hydrate; BIO5192 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	The combination of BIO5192 hydrate (1 mg/kg; i.v.) and Plerixafor (5 mg/kg; s.c.) exert an additive effect on progenitor mobilization[1]. BIO5192 hydrate (30 mg/kg; s.c.; bid; during days 5 through 14) delays paralysis associated with EAE (experimental autoimmune encephalomyelitis)[2]. BIO5192 hydrate (1 mg/kg, i.v.) shows the terminal half-life is 1.1 hours. BIO5192 hydrate (3, 10, and 30 mg/kg; s.c.) shows half-lives of 1.7, 2.7, and 4.7 hours, respectively. The blood plasma curves show that the AUC for the s.c. route of administration increased about 2.5-fold from 5,460 h/ng/mL for the 3mg/kg dose to 14,175 h/ng/mL for the 30 mg/kg[1]. Animal Model: C57BL/6J x 129Sv/J F1 mice[1]
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Cecropin P1, porcine, CAS 125667-96-1



Structure
Cecropin P1, porcine, CAS 125667-96-1

ADDITIONAL INFORMATION

Related Product Information for BIO5192 biochemical

BIO5192 hydrate is a selective and potent integrin alpha4beta1 (VLA-4) inhibitor ($K_d < 10$ pM). BIO5192 hydrate selectively binds to alpha4beta1 ($IC_{50} = 1.8$ nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels[1][2].

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.